Braxia Scientific

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) has reported a significant increase in treatment volumes across its clinics, which rose by 26.2% in fiscal 2023 to 3,516, compared to 2,785 treatments in the previous year. The company said its growth has been driven by increased demand across all five of its clinics. » Mehr auf proactiveinvestors.com

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) announced that Irwin Naturals Inc has terminated the non-binding amended and restated letter of intent (LOI) for a business combination between Irwin and Braxia, which the company called “disappointing”.   The medical research and telemedicine firm, however, said it remains committed to evaluating a number of potential strategic opportunities to create shareholder value in the mental health industry, which continues to evolve and consolidate. » Mehr auf proactiveinvestors.com

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) has reported third-quarter results that show a sharp rise in revenue as the company increased its in-clinic ketamine treatments and continued to expand its US telemedicine platform, KetaMD. The medical research and telemedicine company also updated investors on its proposed acquisition by Irwin Naturals Inc. (CSE:IWIN) after the two companies entered into a non-binding Letter of Intent (LOI) in January. » Mehr auf proactiveinvestors.com